MetaboMed, an Israel-based biopharmaceutical company, has named Ali Fattaey, PhD as its new CEO, it was reported on Wednesday.

The new CEO has more than 20 years of experience in private and public biotech executive management roles focused on cancer drug discovery and development.

Dr Fattaey has held the position of president and chief executive officer of Curis Inc. He has successfully raised funds in the private venture and public markets, hired and built cancer drug development teams, as well as set up strategic partnerships and collaborations within the industry.